Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2022
Q3
Sell
-178,900
Closed -$2.44M 6515
2022
Q2
$2.44M Buy
+178,900
New +$2.96M ﹤0.01% 3384
2021
Q2
Sell
-35,500
Closed -$3.25M 6385
2021
Q1
$3.25M Sell
35,500
-11,500
-24% -$1.12M ﹤0.01% 3331
2020
Q4
$3.81M Buy
+47,000
New +$3.6M ﹤0.01% 3025

JP Morgan Chase's CVAC Position: Q1 2026 in Review

JP Morgan Chase sold out of CureVac (CVAC) in Q1 2026, closing a stake of 123 shares — an estimated $556 sold.

JP Morgan Chase first reported a position in CVAC in Q4 2020 and held it in 16 quarters. The position peaked at $4.08M in Q1 2021. 0 funds tracked by Wall St. Rank hold CVAC as of Q1 2026.

  • JP Morgan Chase reported no remaining CureVac position as of Q1 2026 after selling out during the quarter.
  • JP Morgan Chase sold 123 CureVac shares in Q1 2026, an estimated $556.
  • JP Morgan Chase first reported a position in CureVac in Q4 2020 and held it in 16 quarters.
  • JP Morgan Chase's CureVac position peaked at $4.08M in Q1 2021.
  • 0 funds tracked by Wall St. Rank held CureVac as of Q1 2026.

Based on JP Morgan Chase's 13F filing for Q1 2026, filed 13 May 2026.